STEFANOVICH ROBERT sold $2.8M of CYRX

STEFANOVICH ROBERT (Chief Financial Officer) sold 169,427 shares of Cryoport, Inc. (CYRX) at $16.27 ($2.76M total) on 2026-06-04.

Original reporting
SEC EDGAR · STEFANOVICH ROBERT
Published Jun 9, 2026, 1:11 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 9, 2026, 1:33 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CYRX
Neutral
medium confidence
Mentioned
$CYRX
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CYRXNeutralLow
01

Why it matters

The disclosure may influence short-term sentiment/positioning, but it does not include new guidance, trial results, contracts, or regulatory actions.

02

Market read

Traders may monitor CYRX for any follow-on insider activity or unusual volume, but the filing alone is not a fundamental catalyst.

03

What to watch

The article notes no pre-arranged 10b5-1 plan; traders may still treat the sale as discretionary, but the filing lacks context (e.g., tax liability, diversification needs).

Relevance 6/10Novelty 6/10Timing: after-hours/next-session read-through from the June 8 Form 4 filing

Background

The article reports an SEC Form 4 insider transaction for Cryoport, Inc. (CYRX) by its CFO.

Company-level read

Ticker impact

$CYRXNeutralMedium confidence
Context

Cryoport CFO Robert Stefanovich sold 169,427 shares in an open-market transaction worth about $2.76M, per SEC Form 4 filed June 8.

Expected impact

Low likelihood of a sustained price move; any reaction is likely limited to short-term sentiment/flow effects.

Evidence & confidence

The filing is a primary-source insider transaction, but it provides no new operational/regulatory/financial catalyst beyond the sale itself.

Market effects

Minimal; this is company-specific insider activity with no stated sector-wide catalyst.

None indicated.

None indicated.

Counterpoint

A single CFO open-market sale can be routine (tax/portfolio diversification) and may not reflect negative expectations.

Key entities

  • Cryoport, Inc.

    Subject of the SEC Form 4 insider sale by its CFO.

  • Robert Stefanovich

    Cryoport CFO who sold 169,427 shares in an open-market transaction.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CYRXMed

CryoPort Q3 Earnings Call Highlights

CryoPort reported Q3 supporting 23 commercial therapies and 788 clinical trials. China operations contribute 3-4% of revenue. The company expects five regulatory filings and two potential new therapy approvals in 2026. Guidance is conservative, focusing on existing clients. Expansion plans include new BioServices capabilities in Paris and California, with long-term margin goals of 55% gross and 30% adjusted EBITDA.

$CYRXMed

Cryoport Reports Third Quarter 2026 Financial Results

Cryoport, Inc. (CYRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Cryoport Reports Third Quarter 2026 Financial Results · Third quarter revenue grew 14% year-over-year to $50.2 million · Commercial Cell and Gene Therapy revenue increased 20% year-over-year · Supporting a record 788 global clinical trials and 23 commercially approve

$CYRXMedAI 8/10

Cryoport (CYRX) Q2 2026 Earnings Call Transcript

Cryoport (CYRX) reported Q2 2026 revenue of $49 million, up from prior periods, led by Life Science Services. Life Science Services revenue rose 15% year over year, with biostorage and bioservices up 25%. Support for commercial cell and gene therapy rose 9% to $9.4 million. Adjusted EBITDA turned positive at $0.4 million. Full-year 2026 revenue guidance remains $192 million to $196 million.

$CYRXMed

Cryoport Reports Second Quarter 2026 Financial Results

Cryoport, Inc. (CYRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Cryoport Reports Second Quarter 2026 Financial Results · Second quarter revenue grew 8% year-over-year to $49.0 million · Life Sciences Services revenue increased 15% year-over-year · BioStorage/BioServices revenue grew 25% year-over-year · Supporting 779 global clin